Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer

Criteria:

Histologically confirmed bronchoalveolar carcinoma (BAC) or adenocarcinoma of the lung with BAC features:

Stage IIIB or IV disease:
Patients with stage IIIB disease must be ineligible for definitive combined modality treatment with radiotherapy and chemotherapy

Measurable disease, defined as >= 1 unidimensionally measurable lesion >= 20 mm by conventional techniques or >= 10 mm by spiral CT scan:

Previously irradiated lesions are considered measurable only if lesion progressed after completion of radiotherapy

No unstable brain metastases:

Brain metastases that are stable for ≥ 1 month after completion of prior radiotherapy, stereotactic surgery, or surgery are allowed

Performance status:

ECOG 0-2
Life expectancy >3 months

Hepatic:

Bilirubin normal
AST and ALT =< 2.5 times upper limit of normal

Renal:

Creatinine normal OR creatinine clearance >= 60 mL/min

Cardiovascular:

No symptomatic congestive heart failure
No unstable angina pectoris
No cardiac arrhythmias

No more than 1 prior chemotherapy regimen for advanced BAC:

Prior gefitinib or other known epidermal growth factor receptor (EGFR) inhibitors are not considered a systemic chemotherapy regimen
At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
At least 4 weeks since prior corticosteroids
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception before, during, and for 30 days after completion of study treatment
No ongoing or active infection
No other malignancy within the past 3 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer that is in complete remission
No peripheral neuropathy >= grade 2
No known hypersensitivity to bortezomib, boron, or mannitol
No psychiatric illness or social situation that would preclude study compliance
No other uncontrolled illness
No concurrent routine granulocyte colony-stimulating factors (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF])
At least 2 weeks since prior radiotherapy
Recovered from prior therapy (alopecia allowed)
At least 2 weeks since prior EGFR inhibitors
At least 4 weeks since prior anticonvulsants
No prior bortezomib
No concurrent antiretroviral therapy for HIV-positive patients
No other concurrent investigational agents
No other concurrent anticancer therapy
Concurrent bisphosphonates for bone metastases allowed

Hematopoietic:

Absolute neutrophil count >= 1,500/mm3
Platelet count >= 100,000/mm3